Annette Bakker, PhD, the CEO of Children’s Tumor Foundation, is at the forefront of rare disease research, particularly focusing on a group of diseases known as NF that cause tumors to grow on nerves in the body. These rare cancers, which account for one in four cancer diagnoses in the U.S., often lack standardized care procedures, leading to significant gaps in treatment options for patients. Bakker’s innovative approach involves “drug repositioning,” where she repurposes non-FDA-approved assets for different indications than originally intended. This strategy aims to bring abandoned pharmaceutical assets back to life as effective treatments for rare diseases.
Through collaborations with industry giants like Pfizer, Children’s Tumor Foundation successfully repositioned a shelved compound into mirdametinib, a treatment for neurofibromatosis type 1 that received FDA and European Medicines Agency approvals. This success story not only highlights the potential for transforming neglected assets into valuable therapies but also underscores the commercial viability of such endeavors. The acquisition of SpringWorks Therapeutics by Merck KGaA for $3.5 billion following mirdametinib’s approval further emphasizes the impact of Bakker’s strategy on the biotech landscape.
Bakker’s journey in rare disease research showcases the importance of bridging academia and industry to translate scientific discoveries into tangible treatments for patients. Her dedication to transforming abandoned assets into FDA-approved therapies underscores the complexities and challenges inherent in rare disease research. Bakker emphasizes the need for collaboration between nonprofit organizations, early-stage biotechs, and pharmaceutical companies to drive advancements in treating rare diseases that are often overlooked in traditional drug development pipelines.
AI is poised to play a crucial role in drug development, offering the potential to define more objective endpoints for clinical trials and identify repositioning opportunities for underutilized assets. Bakker envisions AI as a valuable tool for capturing complex patient data, particularly in assessing endpoints like pain and cognition, which are pivotal in evaluating the efficacy of rare disease treatments. By leveraging AI algorithms to analyze massive datasets, researchers can gain deeper insights into disease mechanisms and treatment outcomes, ultimately enhancing the development of novel therapies for rare diseases.
Clinical trial recruitment remains a significant challenge in rare disease research, with a substantial portion of trials failing due to inadequate patient enrollment. Bakker stresses the importance of fostering two-way communication between patients and physicians to enhance recruitment efforts and create patient-centric trial designs. Empowering patients with the necessary information and support to participate in clinical trials is essential for advancing rare disease research and accelerating the development of innovative treatments that address unmet medical needs.
In her advice to young researchers and physicians, Bakker advocates for a balance between confidence and strategic decision-making, urging individuals to assess the value of their pursuits and adapt to unforeseen challenges in their careers. For women in health professions, Bakker underscores the significance of perseverance, competence, and maintaining a sense of humor to navigate the complexities of a male-dominated field. By embracing courage and continuous learning, individuals can overcome obstacles, embrace change, and drive meaningful progress in the field of rare disease research.
Key Takeaways:
– Repositioning abandoned pharmaceutical assets offers a promising avenue for developing effective treatments for rare diseases.
– Collaboration between academia, industry, and nonprofit organizations is essential for advancing rare disease research and translating scientific discoveries into clinical applications.
– AI presents opportunities to enhance drug development processes by defining objective endpoints and identifying repositioning prospects for underexplored therapeutic compounds.
– Improving clinical trial recruitment through patient-centered approaches and effective communication between patients and physicians is crucial for accelerating rare disease research and treatment development.
Tags: clinical trials, rare diseases, biotech
Read more on healio.com